25 November 2015 - Impax Laboratories today announced that the European Commission has granted marketing authorization for Numient (levodopa and carbidopa), a modified-release oral capsule formulation for the symptomatic treatment of adult patients with Parkinson's disease.

For more details, go to: http://investors.impaxlabs.com/Media-Center/Press-Releases/Press-Release-Details/2015/Impax-Receives-European-Commission-Marketing-Authorization-for-NUMIENT-Levodopa-and-Carbidopa-Modified-Release-Capsules-for-the-Symptomatic-Treatment-of-Adult-Patients-with-Parkinsons-Disease/default.aspx